LifeMD, Inc. (LFMD) is a direct-to-patient telehealth company that simplifies healthcare by providing virtual and in-home medical services. The company offers subscription-based access to licensed healthcare professionals and delivers prescription medications, over-the-counter products, and digital solutions. LFMD also operates a SaaS platform for document management.
-
Telehealth - Provides virtual healthcare services, including primary care, chronic disease management, and lifestyle treatments such as weight management, sleep, hair loss, hormonal therapy, and sexual health. Offers prescription and OTC products through a subscription model.
- ShapiroMD - Offers hair loss treatments, including FDA-approved minoxidil and an FDA-cleared medical device.
- RexMD - Focuses on men’s health, offering treatments for erectile dysfunction, premature ejaculation, and hair loss.
- NavaMD - Provides tele-dermatology and skincare solutions for women.
- GLP-1 Weight Management Program - Includes prescriptions for GLP-1 medications, lab work, primary care, and holistic coaching.
-
WorkSimpli - Operates PDFSimpli, a SaaS platform for converting, signing, editing, and sharing PDF documents, generating recurring revenue through subscription services.
You might also like
| Name | Position | External Roles | Short Bio | |
|---|---|---|---|---|
Justin Schreiber ExecutiveBoard | Chief Executive Officer | Justin Schreiber has served as the Chief Executive Officer of LifeMD since 2018 and as Chairman of the Board since 2019. He brings extensive expertise in healthcare, capital markets, and investor relations, playing a pivotal role in the company’s strategic growth. | View Report → | |
Dennis Wijnker Executive | Chief Technology Officer (CTO) | Dennis Wijnker is the Chief Technology Officer at LifeMD, Inc. since December 2021. He previously held senior roles at Doctor Evidence and Parexel/Perceptive Informatics, where he contributed significantly to technology innovation in healthcare. | ||
Jessica Friedeman Executive | Chief Marketing Officer | Jessica Friedeman has served as the Chief Marketing Officer at LifeMD, Inc. since January 2023. She brings nearly 20 years of marketing expertise, previously holding executive roles at Mercury Healthcare, Healthgrades, and Evariant. | ||
Marc Benathen Executive | Chief Financial Officer (CFO) | Director of the Baruch College Alumni Association | Marc Benathen has been serving as the CFO of LifeMD, Inc. since February 2021. He brings over 18 years of experience in financial management and previously served as CFO of Blink Holdings, Inc. from 2017 until January 2021. | |
Dr. Joan LaRovere Board | Independent Director | Co-Founder and Vice President at Virtue Foundation; Director of Innovation and Outcomes and Senior Staff Physician at Boston Children’s Hospital; Assistant Professor of Pediatrics at Harvard Medical School; Professional Advisor at Martin Trust Center for MIT Entrepreneurship; Healthcare Operating Partner at iSelect Fund | Dr. Joan LaRovere has served as an Independent Director at LifeMD, Inc. since February 9, 2023, contributing deep expertise in healthcare innovation and leadership. She has held active roles in healthcare and academia at Virtue Foundation, Boston Children's Hospital, Harvard Medical School, and other organizations. | |
Roberto Simon Board | Board Member and Chairman of the Audit Committee | CFO of Norstella | Roberto Simon is a board member and the Chairman of the Audit Committee at LFMD, recognized as an audit committee financial expert. He joined LFMD's board in 2020 and renewed his director agreements in July 2022, August 2023, and December 2024. | |
William J. Febbo Board | Director | Faculty Member, MIT linQ Program; Board Member, United Nations of Greater Boston | William J. Febbo has served as a Board Director of LifeMD since June 2023 and entered into a consulting services agreement on May 30, 2023 to provide investor relations and strategic business development services. | |
Brad Roberts | Advisor | Brad Roberts served as the Chief Operating Officer of LFMD from December 2020 until his mutual separation on March 8, 2024, and now continues as an advisor. He brings over 16 years of executive experience in direct-to-consumer, FinTech, and healthcare companies. |
-
Given your efforts to transition patients from compounded therapies to branded GLP‑1 medications, how do you plan to mitigate the risk if prior authorization approval rates, even after recent improvements, begin to falter in a more competitive market?
-
You highlighted an 18 percentage point increase in prior authorization approvals for branded GLP‑1 between October and January; what are the key drivers behind that improvement, and how sustainable are they in the face of evolving regulatory and insurance dynamics?
-
With the onboarding of your new pharmacy causing a temporary drop in gross margins, can you detail the specific measures being implemented to normalize margins back to the targeted 88%–90% range and any lingering cost issues that might affect this trajectory?
-
You mentioned that remote patient monitoring via wearables is not on the roadmap for 2025; what are the main challenges or strategic reasons behind this decision, and could delaying this development compromise LifeMD’s competitive edge in virtual care?
-
Your guidance assumes a mid-single-digit revenue contribution from new insured lives in 2025, with expectations to reach 30%–50% in a few years; what operational or market challenges do you foresee in scaling these insurance offerings, and what contingencies are in place if growth stalls?
Research analysts who have asked questions during LifeMD earnings calls.
Sarah James
Cantor Fitzgerald
4 questions for LFMD
Anderson Schock
B. Riley Securities
3 questions for LFMD
David Larsen
BTIG
3 questions for LFMD
Eduardo Martinez-Montes
H.C. Wainwright & Co., LLC
2 questions for LFMD
Steven Valiquette
Mizuho
2 questions for LFMD
Yi Chen
H.C. Wainwright & Co.
2 questions for LFMD
Alex Fuhrman
Craig-Hallum Capital Group LLC
1 question for LFMD
Brooks O'Neil
Lake Street Capital Markets
1 question for LFMD
Jenny Shen
TD Cowen
1 question for LFMD
Kyle Bauser
B. Riley Securities
1 question for LFMD
Ryan Meyers
Lake Street Capital Markets
1 question for LFMD
Steve Dechert
KeyBanc Capital Markets
1 question for LFMD
Notable M&A activity and strategic investments in the past 3 years.
| Company | Year | Details |
|---|---|---|
ResumeBuild | 2022 | In February 2022, WorkSimpli (a majority-owned subsidiary of LifeMD) acquired ResumeBuild for $4.0M upfront plus a contingent consideration of at least $500K, securing all assets related to its subscription-based resume-building SaaS platform; the deal was financed through a promissory note and structured as an asset acquisition under ASC 805 to bolster WorkSimpli’s transformation. |
Cleared Technologies PBC | 2022 | Completed on January 18, 2022, LifeMD acquired Cleared Technologies, a nationwide allergy telehealth platform, with an initial payment of $460K at closing, two subsequent installments of $1.73M each, and a potential earn-out up to $72.8M tied to revenue milestones; the deal’s flexible payment options (cash/stock) and escrow arrangement supported LifeMD’s expansion into direct-to-patient telehealth services in allergy, asthma, and immunology. |
Recent press releases and 8-K filings for LFMD.
- A federal securities fraud class action lawsuit has been filed against LifeMD, Inc. and its executives, alleging they presented a misleadingly optimistic financial picture and growth.
- The lawsuit, Johnston v. LifeMD, Inc., covers the period between May 7, 2025, and August 5, 2025, seeking damages for investors who suffered substantial losses.
- The complaint alleges that LifeMD failed to disclose critical business challenges, including rising customer acquisition costs for its RexMD segment and a higher-than-anticipated patient refund rate in its weight management business, despite reporting strong Q1 2025 results and raising full-year guidance on May 6, 2025.
- The alleged deception unraveled on August 5, 2025, when LifeMD announced Q2 results, missed estimates, and slashed full-year guidance, leading to a stock price plummet of over 44% the following day.
- The Lead Plaintiff Deadline for the lawsuit is October 27, 2025.
- Faruqi & Faruqi, LLP is investigating LifeMD (NASDAQ: LFMD) and a federal securities class action has been filed, alleging the company made false or misleading statements and failed to disclose an overstated competitive position and reckless 2025 guidance.
- The allegations stem from LifeMD's August 5, 2025, announcement of revised 2025 total revenue guidance of $250 to $255 million, down from previous guidance of $268 to $275 million.
- Following this news, LifeMD's stock plummeted 44.8% on August 6, 2025.
- Investors who acquired LifeMD securities between May 7, 2025, and August 5, 2025, and suffered losses are encouraged to contact Faruqi & Faruqi, with the deadline to seek lead plaintiff status set for October 27, 2025.
- A federal securities fraud class action lawsuit has been filed against LifeMD, Inc. and its executives, alleging they presented a misleadingly optimistic image of the company's financial health and growth prospects.
- The lawsuit claims LifeMD concealed critical business challenges, specifically soaring customer acquisition costs in its RexMD segment and a higher-than-expected rate of patient refunds in its weight management business.
- These alleged issues became public on August 5, 2025, when LifeMD announced second-quarter results, missed revenue and earnings per share estimates, and subsequently slashed its full-year guidance, leading to a stock price plummet of over 44% the following day.
- The alleged class period for the lawsuit is May 7, 2025, through August 5, 2025, with a lead plaintiff deadline of October 27, 2025.
- Faruqi & Faruqi, LLP has filed a federal securities class action against LifeMD, Inc. (NASDAQ: LFMD).
- The lawsuit alleges that LifeMD made false and misleading statements by overstating its competitive position and being reckless in raising its 2025 guidance without properly accounting for rising customer acquisition costs.
- Investors who suffered losses between May 7, 2025, and August 5, 2025, are encouraged to act, with the lead plaintiff deadline set for October 27, 2025.
- This action follows LifeMD's August 5, 2025, announcement of revised 2025 total revenue guidance, lowering it from $268-$275 million to $250-$255 million, which caused the stock to plummet 44.8% on August 6, 2025.
- A federal securities fraud class action lawsuit has been filed against LifeMD, Inc. and its executives, alleging the company presented a misleadingly optimistic financial picture and growth guidance.
- The lawsuit, covering the period between May 7, 2025, and August 5, 2025, claims LifeMD failed to disclose critical business challenges, including rising customer acquisition costs for RexMD and a higher-than-anticipated refund rate in its weight management business.
- The alleged deception unraveled on August 5, 2025, when LifeMD announced Q2 results, missed revenue and earnings estimates, and subsequently slashed its full-year guidance, leading to a 44% stock price drop the following day.
- Investors who suffered significant losses during the class period are urged to submit their losses by the Lead Plaintiff Deadline of October 27, 2025.
- Faruqi & Faruqi, LLP is investigating potential securities fraud claims against LifeMD for investors who suffered losses exceeding $75,000 between May 7, 2025, and August 5, 2025.
- The class action alleges that LifeMD executives made false or misleading statements, including overstating the company's competitive position and being reckless in raising 2025 guidance without properly accounting for rising customer acquisition costs.
- On August 5, 2025, LifeMD announced revised 2025 total revenue guidance of $250 million to $255 million, a reduction from the prior $268 million to $275 million.
- Following the revised guidance, LifeMD's stock plummeted 44.8% on August 6, 2025.
- The deadline for investors to seek the role of lead plaintiff in the federal securities class action is October 27, 2025.
- A federal securities fraud class action lawsuit has been filed against LifeMD (NASDAQ: LFMD), alleging that the company and its executives provided investors with a misleading picture of its financial health and growth prospects.
- The lawsuit focuses on the period between May 7, 2025, and August 5, 2025, claiming LifeMD failed to disclose crucial business challenges such as rising customer acquisition costs in its RexMD segment and a higher-than-anticipated refund rate in its weight management business.
- The alleged deception unraveled on August 5, 2025, when LifeMD announced its second-quarter results, missing revenue and earnings per share estimates and subsequently slashing its full-year guidance, which led to a stock price plummet of over 44% the following day.
- The Lead Plaintiff Deadline for investors to participate in the lawsuit is October 27, 2025.
- Faruqi & Faruqi, LLP is investigating potential claims against LifeMD, Inc. (NASDAQ: LFMD) and has filed a federal securities class action lawsuit.
- The complaint alleges that LifeMD made false and/or misleading statements, including overstating its competitive position and providing reckless 2025 guidance without properly accounting for rising customer acquisition costs.
- On August 5, 2025, LifeMD reported its financial results for the second quarter of 2025 and announced revised guidance, expecting total revenue in the range of $250 million to $255 million, compared with previous guidance of $268 million to $275 million.
- Following this news, LifeMD's stock plummeted 44.8% on August 6, 2025.
- Investors who purchased or acquired securities in LifeMD between May 7, 2025, and August 5, 2025, have until October 27, 2025, to seek the role of lead plaintiff in the class action.
- A securities fraud class action lawsuit has been filed against LifeMD, representing investors who purchased securities between May 7, 2025, and August 5, 2025.
- The lawsuit follows LifeMD's disappointing Q2 2025 financial results, where the company missed consensus estimates and significantly reduced its 2025 revenue guidance by 6.7% to 7.3% and adjusted EBITDA guidance by 12% to 13%.
- The complaint alleges LifeMD made false and misleading statements on May 6, 2025, when it raised its full-year 2025 guidance, failing to disclose issues such as rising customer acquisition costs in its RexMD segment and costs related to obesity drugs.
- LifeMD's shares crashed $5.31 (-44%) on August 6, 2025, after the Q2 2025 results were announced.
- The Portnoy Law Firm has initiated an investigation into LifeMD, Inc. for possible securities fraud, potentially leading to a class action lawsuit.
- This investigation follows LifeMD's August 5, 2025, announcement of its Q2 2025 financial results and revised guidance.
- LifeMD's updated revenue projection was lowered to $250 million to $255 million, down from its prior guidance of $268 million to $275 million.
- Following this announcement, LifeMD’s stock price declined by 44.8% on August 6, 2025.